The diagnostic value of serum copeptin levels in an acute pulmonary embolism

Kalkan, Ali Kemal; Öztürk, Derya; Ertürk, Mehmet; Kalkan, Mehmet; Çakmak, Hüseyin Altuğ; Oner, Ender; Uzun, Fatih; Taşbulak, Ömer; Yakisan, Turab; Çelik, Ahmet

doi:10.5603/cj.a2015.0077

Cited by 17 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, copeptin values of patients with RVD were significantly higher than those of patients without RVD (P < 0,05). In a similar study 12 published during the course of our study, it was found that copeptin levels in acute PE patients with RV dysfunction were significantly higher than patients without RV dysfunction, which was consistent with our results. We also found the AUC value as 0.82, the specificity as 69.6% and the sensitivity as 83.0% in ROC curve analysis for the ability of copeptin to detect right ventricular dilation.…”

Section: Discussionsupporting

confidence: 93%

“…In addition, in this study, the AUC value of copeptin for PE diagnosis was found to be 0.84, while sensitivity was 68.1% and specificity was 83.7%. 12 Given the fact that copeptin is thought to be released by many physiological and pathological stimuli such as pain, hypoglycemia, hypoxemia, stroke, infection and shock; it is also expected to be high in acute PE patients. We think that factors such as pain, hypoxia and haemodynamic changes in acute PE cause increase in neurohumoral activity leading to the release of copeptin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between right ventricular dilatation and blood copeptin levels in patients with acute pulmonary embolism

Usul

Özkan

Höke

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

In this study, we aimed to investigate the importance of copeptin in the diagnosis of acute pulmonary embolism, detection of right ventricular dilatation and clinical severity and prognosis of pulmonary embolism. Materials and Methods: In the study three groups were created; Group 1: Pulmonary embolism patients with right ventricular dilatation in echocardiography, Group 2: Pulmonary embolism patients without right ventricular dilatation in echocardiography, Group 3: Healthy people. Five mL of venous blood was collected for the measurement of serum copeptin from the patients and control group. D-dimer and troponin were studied with routine blood samples. Complaints, symptom and physical examination findings, tomography and echocardiography results, laboratory results of patients and treatments they received were recorded for the statistical analysis. Results: Copeptin levels of acute pulmonary embolism patients were significantly higher than healthy individuals (P < 0.001). Copeptin values of Group 1 patients were significantly higher than Group 2 patients and Group 3 patients (P < 0.001). There was a statistically significant difference the levels of copeptin, D-dimer and troponin between patients with right ventricular dilatation and patients without right ventricular dilatation (P < 0.05). AUC value in detecting right ventricular dilatation of copeptin was found to be 0.82, while specificity was 83.3% and sensitivity was 69.6%. Copeptin, D-dimer and troponin levels of patients with increased pulmonary artery pressure were statistically significantly higher than patients with normal pulmonary artery pressure (P < 0.05). Conclusion: Copeptin can be used in the diagnosis of acute pulmonary embolism and in the detection of right ventricular dilatation in pulmonary embolism. K E Y W O R D S biomarker, echocardiography, heart failure, prognosis, pulmonary embolism 1 | INTRODUCTION Pulmonary embolism (PE) is a common life-threatening cardiopulmonary disorder in which a venous thrombus obstructs pulmonary arterial bed. 1,2 The obstruction of pulmonary arterial bed may cause acute but reversible right ventricular failure. 1,2 Right ventricular dysfunction is an important prognostic value in patients with PE. In patients with right How to cite this article: Usul E, Ozkan S, Höke MH, Kaya AE, Ucar F, Cimen T. Relationship between right ventricular dilatation and blood copeptin levels in patients with acute pulmonary embolism.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Relationship between right ventricular dilatation and blood copeptin levels in patients with acute pulmonary embolism

Usul

Özkan

Höke

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…The researchers determined that copeptin >17.95 pmol/L levels predicted complicated clinical course (CCC) with a specificity of 49.5% and a sensitivity of 100% while the AUC values for the copeptin in predicting CCC was 0.811 (95% CI: 0.676‐0.927). In a study conducted by Kalkan et al, it was reported that the group including patients with acute PE had higher levels of copeptin compared to those without acute PE (7.76 ± 4.4 vs 3.81 ± 1.34 ng/mL; P < 0.001) . The ROC analysis showed that copeptin levels >4.84 ng/mL had a 68.1% sensitivity and 83.7% specificity for the diagnosis of acute PE in this study.…”

Section: Discussionsupporting

confidence: 57%

“…The cut‐off of serum copeptin level was 24 pmol/L for prognostic value in PE patients in two study, and also as 7.8 ng/mL in our study . In addition, the cut‐off value of copeptin level was 4.84 ng/dL for the diagnostic predictor in another study . The differences of copeptin’s cut‐off value may be caused by unit differences and different patient population.…”

Section: Discussionsupporting

confidence: 53%

See 1 more Smart Citation

Prognostic value of copeptin in patients with acute pulmonary thromboembolism

Deveci

Öner

Telo

et al. 2019

Clinical Respiratory J

View full text Add to dashboard Cite

Background and Aims The aim of this study was to determine the level of copeptin, which is one of the new cardiac markers in acute pulmonary thromboembolism (PE) cases, and to determine the relationship between the severity of the disease, risk classification and hospital, first month, third month and 3‐month total mortality. Methods The study included 100 cases with PE and 60 healthy control subjects. Copeptin was measured in control group. The risk grade of the cases was determined according to the sPESI index. Patients survival data at the first and third months were determined. This study was performed in patients with strict exclusion criteria for comorbidities known to be associated with increased risk of PE. Results sPESI was ≥1 in 68 (68%) of patients with acute PE. Mean serum copeptin levels were found statistically higher in patients with high risk compared to low‐risk cases and controls (9.18 ± 3.29, 6.47 ± 2.29, and 5.26 ± 2.15, P < 0.0001, respectively). When the cut‐off value of copeptin was taken as ≥7.87 with ROC analysis for predicting high sPESI score, the sensitivity of the copeptin was 78% and the specificity was 62% (AUC = 0.74, 95% CI = 0.63–0.85, P < <0.0001). When cases divided in the groups according to the cut‐off value as 7.87, first month hospital mortality and 3‐month total mortality rate was found statistically higher in patients with copeptin ≥7.87 (χ2 = 5.33 P < 0.05, χ2 = 3.88, P < 0.05 and χ2 = 4.26, P < 0.05 respectively). Conclusions The results of our study showed that increased serum copeptin levels might predict the severity of PE as well as a promising marker of early mortality in high‐risk cases according to sPESI.

show abstract